News Release



Investor Contact:
Maureen Resac

Maureen.Resac@Adtalem.com
312-651-1481

Media Contact: John Kristoff John.Kristoff@Adtalem.com 312-651-1437

Adtalem Global Education Announces Fiscal Third Quarter 2020 Results

CHICAGO – May 5, 2020 – Adtalem Global Education Inc. (NYSE: ATGE), a leading workforce solutions provider, today reported academic, operating and financial results for its fiscal 2020 third quarter ended March 31, 2020.

"We reported a solid third quarter, delivering both revenue growth and enhanced profitability through new student enrollments and employer partnerships, and prudent cost management across the business. As the COVID-19 crisis escalated near the end of the quarter, our experienced team reacted quickly, leveraging our existing robust eLearning infrastructure to move more than 15,000 medical and healthcare students to online platforms within a week, and with minimal disruption," said Lisa Wardell, chairman and CEO of Adtalem. "While the ultimate impact on the global economy from this pandemic is far from known at this point, we remain well-positioned with offerings focused on the critical industries of healthcare and financial services, coupled with our strong online capabilities and superior student outcomes."

"Adtalem has significant cash on hand and ample liquidity, bolstered most recently by the proceeds from the Adtalem Brazil divestiture which closed in April ahead of our original fiscal 2021 Q1 closing date estimate. We maintain a focused portfolio in healthcare where employer needs continue to increase, and in financial services in areas that will remain critical to business operations and integrity through any economic consequences of the current crisis. Our leadership team has demonstrated its ability to successfully navigate crises in the past, and we are confident that we will emerge from this crisis as a stronger, well positioned business with attractive opportunities for growth," concluded Wardell.

Financial Highlights

Selected financial data for the three months ended March 31, 2020:

Revenue of \$271.5 million increased 4.9% compared with the prior year

- Diluted earnings per share was \$2.83 compared with \$0.64 in the prior year; diluted earnings per share from continuing operations, excluding special items, was \$0.81, compared to \$0.64 in the prior year
- Operating income from continuing operations was \$54.5 million compared with \$45.6 million in the prior year; operating income from continuing operations, excluding special items, was \$56.3 million, an 18.0% increase compared with the prior year
- Net income attributable to Adtalem was \$150.8 million, driven by a pre-tax unrealized gain of \$111.8 million from a currency hedge associated with our Adtalem Brazil transaction, compared with \$37.9 million in the prior year; net income from continuing operations attributable to Adtalem, excluding special items, was \$43.2 million, a 15.7% increase compared with the prior year
- Approximately 1.2 million shares of common stock were repurchased during the third quarter of fiscal
 2020 at an average purchase price of \$31.67 for a total of \$36.9 million

Selected financial data for the nine months ended March 31, 2020:

- Revenue of \$792.3 million increased 5.7% compared with the prior year
- Diluted earnings per share was \$3.13 compared with \$0.76 in the prior year; diluted earnings per share from continuing operations, excluding special items, was \$1.70, compared to \$1.64 in the prior year
- Operating income from continuing operations was \$120.5 million compared with \$101.0 million in the prior year; operating income from continuing operations, excluding special items, was \$126.1 million, a 3.5% decrease compared with the prior year
- Net income attributable to Adtalem was \$170.7 million, driven by a pre-tax unrealized gain of \$83.8 million from a currency hedge associated with our Adtalem Brazil transaction, compared with \$45.7 million in the prior year; net income from continuing operations attributable to Adtalem, excluding special items, was \$93.0 million, a 5.4% decrease compared with prior year
- Approximately 3.8 million shares of common stock were repurchased during the first nine months of fiscal 2020 at an average purchase price of \$35.66 for a total of \$136.9 million

Fiscal 2020 third quarter results contained special items including total pre-tax restructuring charges of \$1.9 million (\$10.3 million for the nine months ended March 31, 2020), the majority of which are related to Adtalem's home office real estate consolidations and workforce reductions which were not related to the COVID-19 pandemic. In addition, a pre-tax unrealized gain of \$111.8 million was recorded in the third quarter on the deal-contingent hedge arrangement entered into in connection with the sale of Adtalem Brazil completed on April 24, 2020. The arrangement hedged the Brazilian Real denominated purchase price through mitigation of the currency exchange rate risk. This mark to market gain is non-cash and did not affect the proceeds upon closing.

Segment Highlights

Medical and Healthcare

Third quarter segment revenue increased 1.7% to \$227.3 million compared with the prior year.

Chamberlain revenue in the third quarter increased 5.4% compared with the prior year. New student enrollment for the January 2020 and March 2020 sessions increased 11.2% and 12.7% compared with the prior year, respectively, while total student enrollment for the January 2020 and March 2020 sessions increased 4.6% and 5.1%, respectively, compared with the prior year.

Revenue in the third quarter for the medical and veterinary schools decreased 3.3% compared with the prior year, with the majority of that decline driven by COVID-19 resulting from reduced clinical weeks in March.

Segment operating income in the third quarter increased 6.9% to \$56.7 million compared with the prior year. Excluding special items, segment operating income in the third quarter increased 8.7% to \$57.6 million. The increase in segment operating income is the result of strong enrollment for Chamberlain and efforts to reduce travel and discretionary spend, offset by corporate costs that were previously allocated to our former Business and Law segment.

Financial Services

Third quarter segment revenue increased 22.8% to \$44.1 million compared with the prior year. Becker Accounting revenue increased 5.3% compared with the prior year. Third quarter segment revenue included \$8.5 million of revenue from the May 2019 acquisition of OnCourse Learning, which more than offset the decrease in revenue from the sale of Becker's healthcare assets. Segment operating income decreased 17.6% to \$4.2 million compared with the prior year. The decrease in segment operating income is the result of corporate costs that were previously allocated to our former Business and Law segment.

Adtalem Outlook

While the near-term financial impact of the COVID-19 pandemic is rapidly evolving and difficult to measure, based on current visibility, there is wider range of potential projected outcomes than normal for the fiscal fourth quarter. Despite confidence in the Adtalem's ability to exit this period of disruption in a position of strength, Adtalem will not provide fiscal year guidance and withdraws its previously issued guidance for fiscal 2020.

Conference Call and Webcast Information

Adtalem will hold a conference call to discuss its fiscal 2020 third quarter on Tuesday, May 5, 2020, at 4 p.m. CT (5 p.m. ET). The conference call will be led by Lisa Wardell, chairman and chief executive officer, and Mike Randolfi, senior vice president and chief financial officer.

For those participating by telephone, dial 877-407-6184 (United States) or +1 201-389-0877 (outside the United States) and request the "Adtalem Call" or use conference ID: 13700577. Adtalem will also broadcast the conference call live on the web at:

https://78449.themediaframe.com/dataconf/productusers/age/mediaframe/36492/indexl.html.

Please access the website at least 15 minutes prior to the start of the call to register, download and install any necessary audio software.

Adtalem will archive a replay of the call until June 5, 2020. To access the replay, dial 877-660-6853 (United States) or +1 201-612-7415 (outside the United States), conference ID: 13700577, or visit the Adtalem website at: https://investors.adtalem.com/overview/default.aspx.

About Adtalem Global Education

The purpose of Adtalem Global Education is to empower students to achieve their goals, find success, and make inspiring contributions to our global community. Adtalem Global Education Inc. (NYSE: ATGE; member S&P MidCap 400 Index) is a leading global education provider and the parent organization of American University of the Caribbean School of Medicine, Association of Certified Anti-Money Laundering Specialists, Becker Professional Education, Chamberlain University, EduPristine, OnCourse Learning, Ross University School of Medicine and Ross University School of Veterinary Medicine. For more information, please visit adtalem.com and follow us on Twitter (@adtalemglobal) and LinkedIn.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding the future impacts of the COVID-19 pandemic. Forward-looking statements can also be identified by words such as "future," "believe," "expect," "anticipate," "estimate," "plan," "intend," "may," "will," "would," "could," "can," "continue," "preliminary," "range," and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. These risk and uncertainties include the risk factors described in Item 1A. "Risk Factors" of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the Securities and Exchange Commission (SEC) on August 28, 2019 and our other filings with the SEC. These forward-looking statements are based on information available to us as of the date any such statements are made, and we do not undertake any obligation to update any forward-looking statement, except as required by law.

Adtalem Global Education Student Enrollments ⁽¹⁾	3Q 2020	3Q 2019	% Change
New students	3,559	3,197	+11.3%
Total students	39,391	37,652	+4.6%
Chamberlain University			
January Session	F 202	4.750	.44.00/
New students Total students	5,293	4,759	+11.2% +4.6%
rotal students	33,850	32,354	+4.0%
March Session			
New students ⁽²⁾	3,073	2,726	+12.7%
Total students	33,748	32,104	+5.1%
Medical and Veterinary ⁽³⁾			
January Semester	406	474	. 2 20/
New students	486 5.643	471 5 5 4 9	+3.2%
Total students	5,643	5,548	+1.7%

- 1) Includes the most recently reported enrollment sessions at Adtalem's postsecondary institutions, excluding Adtalem Brazil
- 2) Post-licensure online programs only; Pre-licensure campus-based programs start in September, January and May; Total students includes pre- and post-licensure enrollment
- 3) Includes enrollments in its medical and veterinary preparatory programs

Adtalem Global Education Inc. Consolidated Balance Sheets (unaudited) (in thousands, except par value)

	March 31, 2020			June 30, 2019	March 31 2019		
Assets:				_			
Current assets:							
Cash and cash equivalents	\$	167,771	\$	204,202	\$	230,700	
Investments in marketable securities		7,754		8,680		8,341	
Restricted cash		807		1,022		391	
Accounts receivable, net		98,732		83,560		89,578	
Prepaid expenses and other current assets		126,785		29,313		44,524	
Current assets held for sale		142,417		177,923		166,557	
Total current assets		544,266		504,700		540,091	
Noncurrent assets:			_				
Property and equipment, net		286,346		283,433		279,387	
Operating lease assets		188,629					
Deferred income taxes		15,066		18,314		19,199	
Intangible assets, net		290,092		297,989		237,013	
Goodwill		686,235		687,256		627,685	
Other assets, net		84,825		52,113		54,386	
Other assets, net Other assets held for sale		,		398,891		390,942	
		348,561	_				
Total noncurrent assets	<u>_</u>	1,899,754	_	1,737,996	_	1,608,612	
Total assets	\$	2,444,020	\$	2,242,696	\$	2,148,703	
Liabilities and shareholders' equity:							
Current liabilities:							
Accounts payable	\$	33,932	\$	53,385	\$	39,092	
Accrued payroll and benefits		40,373		46,664		39,439	
Accrued liabilities		60,458		76,529		74,614	
Deferred revenue		120,047		95,944		108,370	
Current operating lease liabilities		51,926		_		_	
Current portion of long-term debt		3,000		3,000		3.000	
Current liabilities held for sale		34,950		36,109		44,690	
Total current liabilities		344,686	_	311,631	_	309,205	
Noncurrent liabilities:		344,000	_	311,031		307,203	
		116 610		209.004		200 500	
Long-term debt		446,610		398,094		288,589	
Long-term operating lease liabilities		179,195		20. 426		22.270	
Deferred income taxes		28,147		29,426		33,278	
Other liabilities		91,011		86,326		88,190	
Noncurrent liabilities held for sale		56,850	_	16,146		16,372	
Total noncurrent liabilities		801,813	_	529,992		426,429	
Total liabilities		1,146,499		841,623		735,634	
Commitments and contingencies							
Redeemable noncontrolling interest		2,962		9,543		8,482	
Shareholders' equity:							
Common stock, \$0.01 par value per share, 200,000 shares authorized; 51,802, 55,303, and 56,954							
shares outstanding as of March 31, 2020, June 30, 2019, and March 31, 2019, respectively		806		801		801	
Additional paid-in capital		499,703		486,061		483.043	
Retained earnings		2.183,620		2.012.902		1.964.169	
Accumulated other comprehensive loss		(276,379)		(137,290)		(148,706)	
Treasury stock, at cost, 28,790, 24,830, and 23,149 shares as of March 31, 2020, June 30, 2019, and		(2.0,5/)		(107,270)		(1.0,700)	
March 31, 2019, respectively		(1,113,191)		(970,944)		(894,720)	
Total shareholders' equity		1,294,559	_	1,391,530		1,404,587	
± *	¢.		ф		ф		
Total liabilities and shareholders' equity	3	2,444,020	\$	2,242,696	\$	2,148,703	

Adtalem Global Education Inc. Consolidated Statements of Income (unaudited)

(in thousands, except per share data)

	Three Months Ended					Nine Months Ended						
		Marc	ch 31			Marc	h 31					
		2020		2019		2020		2019				
Revenue	\$	271,487	\$	258,703	\$	792,272	\$	749,603				
Operating cost and expense:												
Cost of educational services		118,712		120,192		374,004		349,803				
Student services and administrative expense		96,434		90,746		292,169		269,161				
Restructuring expense		1,854		2,186		10,339		45,194				
Gain on sale of assets		_		_		(4,779)		_				
Settlement gain								(15,571)				
Total operating cost and expense		217,000		213,124		671,733		648,587				
Operating income from continuing operations		54,487		45,579		120,539		101,016				
Other income (expense):												
Interest and dividend income		782		1,062		2,675		3,204				
Interest expense		(5,191)		(4,786)		(15,585)		(14,710)				
Investment (loss) gain		(1,548)		715		(1,106)		(407)				
Gain on derivative		111,838				83,832						
Net other income (expense)		105,881		(3,009)		69,816		(11,913)				
Income from continuing operations before income taxes		160,368		42,570		190,355		89,103				
Provision for income taxes		(6,937)		(7,843)		(18,213)		(17,370)				
Income from continuing operations		153,431		34,727		172,142		71,733				
Discontinued operations:												
(Loss) income from discontinued operations before income taxes		(5,947)		3,222		(5,536)		1,271				
Loss on disposal of discontinued operations before income taxes				(265)				(32,979)				
Benefit from income taxes		3,228		182		3,778		5,762				
(Loss) income from discontinued operations		(2,719)		3,139		(1,758)		(25,946)				
Net income		150,712		37,866		170,384		45,787				
Net loss attributable to redeemable noncontrolling interest from continuing operations		120		113		334		265				
Net income attributable to redeemable noncontrolling interest from discontinued operations	_		_	(74)	φ.		<u>_</u>	(382)				
Net income attributable to Adtalem Global Education	\$	150,832	\$	37,905	\$	170,718	\$	45,670				
Amounts attributable to Adtalem Global Education:												
Net income from continuing operations	\$	153,551	\$	34,840	\$	172,476	\$	71,998				
Net (loss) income from discontinued operations		(2,719)		3,065		(1,758)		(26,328)				
Net income attributable to Adtalem Global Education	\$	150,832	\$	37,905	\$	170,718	\$	45,670				
Earnings (loss) per share attributable to Adtalem Global Education: Basic:												
Continuing operations	\$	2.90	\$	0.60	\$	3.19	\$	1.22				
Discontinued operations	\$	(0.05)	\$	0.05	\$	(0.03)	\$	(0.44)				
Net	\$ \$	2.85	\$	0.65	\$	3.15	\$	0.77				
Diluted:	Ψ	2.03	Ψ	0.03	Ψ	3.13	Ψ	0.77				
Continuing operations	\$	2.88	\$	0.59	\$	3.16	\$	1.20				
Discontinued operations	\$	(0.05)	\$	0.05	\$	(0.03)	\$	(0.44)				
Net	\$	2.83	\$	0.64	\$	3.13	\$	0.76				
Weighted-average shares outstanding:												
Basic shares		52,955		58,061		54,117		59,199				
Diluted shares		53,319		58,802		54,576		60,004				

Adtalem Global Education Inc. Consolidated Statements of Cash Flows (unaudited) (in thousands)

Nine Months Ended	l
March 31,	

	2020	iur cir o 1,	2019
Operating activities:			
Net income	\$ 170,38	4 \$	45,787
Loss from discontinued operations	1,75	8	25,946
Income from continuing operations	172,14	2	71,733
Adjustments to reconcile net income to net cash provided by operating activities:			
Stock-based compensation expense	11,32		10,369
Amortization and adjustments to operating lease assets	32,36		_
Depreciation	25,77		24,726
Amortization	8,86		5,990
Provision for bad debts	12,95		5,150
Deferred income taxes	1,82		23,717
Loss on disposals, accelerated depreciation, and adjustments to property and equipment	14		41,082
Realized and unrealized loss on investments	1,10		407
Realized gain on sale of assets	(4,77	9)	
Insurance settlement gain	-	_	(15,571)
Unrealized gain on derivative	(83,83	2)	_
Changes in assets and liabilities:			
Accounts receivable	(19,92		(24,511)
Prepaid expenses and other current assets	(17,12		(11,948)
Accounts payable	(18,49		(4,433)
Accrued payroll and benefits	(6,29		(12,755)
Accrued liabilities	(4,81		6,156
Deferred revenue	24,10		9,423
Operating lease liabilities	(41,62		
Other assets and liabilities	(2,04		(22,355)
Net cash provided by operating activities-continuing operations	91,68		107,180
Net cash provided by operating activities-discontinued operations	13,84		21,355
Net cash provided by operating activities	105,53	1	128,535
Investing activities:			
Capital expenditures	(31,93	4)	(45,269)
Insurance proceeds received for damage to buildings and equipment	-	-	35,706
Proceeds from sales of marketable securities	1,57		1,625
Purchases of marketable securities	(1,75	5)	(6,070)
Proceeds from sale of assets	6,42		_
Cash received on purchase price adjustment	9	2	_
Loan to DeVry University			(10,000)
Net cash used in investing activities-continuing operations	(25,60	4)	(24,008)
Net cash used in investing activities-discontinued operations	(3,80	3)	(7,417)
Cash and restricted cash transferred in divestitures of discontinued operations			(48,876)
Net cash used in investing activities	(29,40	7)	(80,301)
Financing activities:			
Proceeds from exercise of stock options	2,27	6	16,825
Employee taxes paid on withholding shares	(5,31	5)	(6,527)
Proceeds from stock issued under Colleague Stock Purchase Plan	_	_	421
Repurchases of common stock for treasury	(136,88		(176,903)
Borrowings under credit facility	225,00		_
Repayments under credit facility	(177,25		(2,250)
Proceeds from down payment on seller loan	5,20		_
Payment for purchase of redeemable noncontrolling interest of subsidiary	(6,24	7)	
Net cash used in financing activities-continuing operations	(93,22	5)	(168,434)
Net cash used in financing activities-discontinued operations	(2,92	0)	(2,154)
Net cash used in financing activities	(96,14	5)	(170,588)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(27,90	7)	(449)
Net decrease in cash, cash equivalents and restricted cash	(47,92	8)	(122,803)
Cash, cash equivalents and restricted cash at beginning of period	300,46	7	444,405
Cash, cash equivalents and restricted cash at end of period	252,53	9	321,602
Less: cash, cash equivalents and restricted cash of discontinued operations at end of period	83,96		90,511
Cash, cash equivalents and restricted cash at end of period	\$ 168,57		231,091
,	+ 100,57		201,071

Adtalem Global Education Inc. Segment Information (unaudited) (in thousands)

Three Months Ended

March 31

Nine Months Ended

		Wiaich 31,				March 31,							
	2020		2019		Increase (Decrease)	2020		2019		Increase (Decrease)			
Revenue:													
Medical and Healthcare	\$	227,344	\$	223,575	1.7 %	\$	655,011	\$	638,302	2.6 %			
Financial Services		44,143		35,935	22.8 %		137,261		113,723	20.7 %			
Home Office and Other				(807)	NM				(2,422)	NM			
Total consolidated revenue	\$	271,487	\$	258,703	4.9 %	\$	792,272	\$	749,603	5.7 %			
Operating income (loss):									_				
Medical and Healthcare	\$	56,749	\$	53,093	6.9 %	\$	126,432	\$	115,396	9.6 %			
Financial Services		4,190		5,086	(17.6)%		10,860		19,469	(44.2)%			
Home Office and Other		(6,452)		(12,600)	48.8 %		(16,753)		(33,849)	50.5 %			
Total consolidated operating income	\$	54,487	\$	45,579	19.5 %	\$	120,539	\$	101,016	19.3 %			

Non-GAAP Financial Measures and Reconciliations

We believe that certain non-GAAP financial measures provides investors with useful supplemental information regarding the underlying business trends and performance of Adtalem's ongoing operations and is useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should be not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to non-GAAP reconciliation tables:

Net income from continuing operations attributable to Adtalem excluding special items (most comparable GAAP measure: net income attributable to Adtalem) – Measure of Adtalem's net income attributable to Adtalem adjusted for restructuring expense, gain on sale of assets, settlement gain, gain on derivative, tax charges related to the divestiture of DeVry University, and loss (income) from discontinued operations.

Earnings per share from continuing operations excluding special items (most comparable GAAP measure: earnings per share) — Measure of Adtalem's diluted earnings per share adjusted for restructuring expense, gain on sale of assets, settlement gain, gain on derivative, tax charges related to the divestiture of DeVry University, and loss (income) from discontinued operations.

Operating income from continuing operations excluding special items (most comparable GAAP measure: operating income from continuing operations) – Measure of Adtalem's operating income from continuing operations adjusted for restructuring expense, gain on sale of assets, and settlement gain. This measure is applied on a consolidated and segment basis, depending on the context of the discussion.

A description of special items in our non-GAAP financial measures described above are as follows:

- Restructuring charges primarily related to the sale of Becker's courses for healthcare students, real estate consolidations and workforce reductions at Adtalem's home office, and the closing of the Ross University School of Medicine ("RUSM") campus in Dominica.
- Gain on the sale of Adtalem's Columbus, Ohio, campus facility.
- Settlement gain related to the final insurance settlement related to Hurricanes Irma and Maria at the American University of the Caribbean School of Medicine ("AUC") and RUSM.
- Gain on the deal-contingent foreign currency hedge arrangement entered into in connection with the sale of Adtalem Brazil to economically hedge the Brazilian Real denominated purchase price through mitigation of the currency exchange rate risk.
- Tax charges related to the divestiture of DeVry University.
- Discontinued operations include the operations of Adtalem Brazil, Carrington, and DeVry University.

	Three Months Ended March 31,					Nine Months Ended March 31,						
	2020		2019		Increase (Decrease)	2020		2019		Increase (Decrease)		
Medical and Healthcare:	_	2020	_	2017	(Beereuse)	_	2020	_	2017	(Decrease)		
Operating income (GAAP)	\$	56,749	\$	53.093	6.9 %	\$	126,432	\$	115,396	9.6 %		
Restructuring expense		810		(133)	NM		1,354		41,327	(96.7)%		
Settlement gain		_			NM		_		(15,571)	NM		
Operating income excluding special items (non-GAAP)	\$	57,559	\$	52,960	8.7 %	\$	127,786	\$	141,152	(9.5)%		
Financial Services:												
Operating income (GAAP)	\$	4,190	\$	5,086	(17.6)%	\$	10,860	\$	19,469	(44.2)%		
Restructuring expense					NM		3,116			NM		
Operating income excluding special items (non-GAAP)	\$	4,190	\$	5,086	(17.6)%	\$	13,976	\$	19,469	(28.2)%		
Home Office and Other:												
Operating loss (GAAP)	\$	(6,452)	\$	(12,600)	48.8 %	\$	(16,753)	\$	(33,849)	50.5 %		
Restructuring expense		1,044		2,319	(55.0)%		5,869		3,867	51.8 %		
Gain on sale of assets					NM		(4,779)	_		NM		
Operating loss excluding special items (non-GAAP)	\$	(5,408)	\$	(10,281)	47.4 %	\$	(15,663)	\$	(29,982)	47.8 %		
Adtalem Global Education:												
Operating income (GAAP)	\$	54,487	\$	45,579	19.5 %	\$	120,539	\$	101,016	19.3 %		
Restructuring expense		1,854		2,186	(15.2)%		10,339		45,194	(77.1)%		
Gain on sale of assets		_		_	NM		(4,779)		_	NM		
Settlement gain					NM			_	(15,571)	NM		
Operating income excluding special items (non-GAAP)	\$	56,341	\$	47,765	18.0 %	\$	126,099	\$	130,639	(3.5)%		

Adtalem Global Education Inc. Non-GAAP Earnings Disclosure (unaudited)

(in thousands, except per share data)

	Three Months Ended March 31,					Nine Months Ended March 31,					
		2020	2019			2020		2019			
Net income attributable to Adtalem (GAAP)	\$	150,832	\$	37,905	\$	170,718	\$	45,670			
Restructuring expense		1,854		2,186		10,339		45,194			
Gain on sale of assets				_		(4,779)					
Settlement gain				_		_		(15,571)			
Gain on derivative		(111,838)		_		(83,832)					
Tax charges related to the divestiture of DeVry University				_				1,526			
Income tax impact on non-GAAP adjustments (1)		(361)		328		(1,165)		(4,795)			
Loss (income) from discontinued operations		2,719		(3,065)		1,758		26,328			
Net income from continuing operations attributable to Adtalem											
excluding special items (non-GAAP)	\$	43,206	\$	37,354	\$	93,039	\$	98,352			

⁽¹⁾ Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.

		Three Mor	 nded	Nine Months Ended March 31,					
		2020	2019		2020		2019		
Earnings per share, diluted (GAAP)	\$	2.83	\$ 0.64	\$	3.13	\$	0.76		
Effect on diluted earnings per share:									
Restructuring expense		0.03	0.04		0.19		0.75		
Gain on sale of assets		-	-		(0.09)		-		
Settlement gain		-	-		-		(0.26)		
Gain on derivative		(2.10)	-		(1.54)		-		
Tax charges related to the divestiture of DeVry University		-	-		-		0.03		
Income tax impact on non-GAAP adjustments (1)		(0.01)	0.01		(0.02)		(0.08)		
Loss (income) from discontinued operations		0.05	 (0.05)		0.03		0.44		
Earnings per share from continuing operations excluding special									
items, diluted (non-GAAP)	\$	0.81	\$ 0.64	\$	1.70	\$	1.64		
Diluted shares used in EPS calculation	•	53,319	58,802		54,576		60,004		

⁽¹⁾ Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.